XK and influenza: Thus far, there has been limited success to obtain GMP-grade purified or recombinant NA for demonstration of clinical efficacy and the mRNA platform offers an opportunity to provide an improved influenza vaccine formulation that expresses not only an HA protein but also a properly folded NA protein for induction of a robust neutralizing antibody response.